Former Global Pharmacovigilance and Clinical Safety Physician Otsuka Pharmaceuticals
Chris Stein, MD, PhD, was recruited by Life Science Partner to serve as Director, Medical Safety Physician for Allergan where he will oversee Pharmacovigilance for Allergan’s CNS drug portfolio.
In his previous role at Otsuka, Stein partnered with safety physicians at Bristol Myers Squibb to co-market the block buster drug, Abilify, and formulate a regulatory compliance strategy and risk management plan while providing signal evaluation and drug safety reporting.
“Intelligent, articulate and passionate about pharmacovigilance, Stein will be able to hit the ground running in his CNS role for Allergan’s pharmacovigilance team,” states Tom Callaway, MD, Founder and President of Life Science Partner. “He brings exceptional analytical and writing skills to be a great addition to the team.”
Chris Stein earned his Bachelor of Science Degree in Biology and Computer Science in 1984 from the Southwest Missouri State University. He completed his MD and PhD from the St. Louis University School of Medicine and his MPH from the University of Kentucky College of Public Health.